Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

24 September 2024

Industry Investors Make Case for Paris-like AMR Guidance

In an article for ESG Investor on investors’ efforts in the fight against AMR, Alice Tchernookova interviewed Suzi van Es, the Foundation’s Investor Engagement Manager.

Direct links

Read the full article

The article highlights the urgent threat of AMR and the important role of investors in tackling this global challenge. It discusses the renewed calls for global alignment from 80 global investors, urging world leaders to adopt a unified, evidence-based approach to combat AMR. Building on a statement released in May, the investors highlight the critical need for global cooperation, sustained funding, and innovative solutions. They warn that without significant action, AMR could result in substantial economic losses and millions of deaths.  

“With growing resistance, time is running out. You could even say we’ve run out of time,” The article quotes Suzi van Es, Investor Engagement Manager at the Foundation, “People need to be action oriented. This is about us achieving right now – rather than mapping or understanding roles and responsibilities.” 

Resource Centre

Explore our research reports and publications
Featured Research

How can pharma get the few promising drugs in development to patients battling superbugs?

23 May 2024
Media

Faced with fewer superbug-beating drugs, how can pharma get more promising medicines to patients?

28 May 2024
Research

How have companies responded to their AMR Benchmark Opportunities?

21 November 2023

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved